Business

Cipla to Market Eli Lilly’s Flagship Weight-Loss Drug in India Under New Brand

The drug, based on tirzepatide — a dual GIP and GLP-1 receptor agonist known for its efficacy in treating type 2 diabetes and obesity — will be marketed by Cipla as “Yurpeak”.

• By Newsdesk
• Mumbai
• Oct 25, 2025

Business

In a major development for India’s fast-growing diabetes and obesity treatment segment, Cipla Ltd has entered into a strategic partnership with global pharmaceutical major Eli Lilly & Co. to market Lilly’s blockbuster weight-management therapy under a new brand name in India.

The drug, based on tirzepatide — a dual GIP and GLP-1 receptor agonist known for its efficacy in treating type 2 diabetes and obesity — will be marketed by Cipla as “Yurpeak”. While Lilly will continue to manufacture the drug, Cipla will take charge of its distribution and marketing across the country.

Yurpeak will be introduced as a once-weekly pre-filled injector pen available in six dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The pricing will remain at par with Lilly’s existing offering of the same molecule in India.

For Eli Lilly, the collaboration underscores its focus on expanding access to its advanced diabetes and obesity treatments to a wider patient base. Cipla’s robust domestic presence and strong chronic-care portfolio are expected to enhance the reach of the therapy beyond metropolitan markets.

Industry experts note that with India witnessing a sharp rise in obesity and lifestyle-related disorders, the partnership could accelerate the availability of cutting-edge metabolic treatments and reshape the domestic weight-management segment.